Pizensy FDA Approval History
Last updated by Judith Stewart, BPharm on March 18, 2020.
FDA Approved: Yes (First approved February 12, 2020)
Brand name: Pizensy
Generic name: lactitol
Dosage form: Powder for Oral Solution
Company: Braintree Laboratories Inc.
Treatment for: Chronic Idiopathic Constipation
Pizensy (lactitol) is an osmotic laxative indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
- Pizensy is supplied as a powder for oral solution. The powder can be mixed with water, juice or other common beverages (coffee, tea, soda). The recommended adult dosage is 20 grams orally once daily, preferably with meals.
- Oral medications should be administered at least 2 hours before, or 2 hours after taking Pizensy.
- Patients should stop taking Pizensy and contact their healthcare provider if they experience persistent loose stools.
- Common adverse reactions (≥ 3%) include upper respiratory tract infection, flatulence, diarrhea, increased blood creatinine phosphokinase, abdominal distension, and increased blood pressure.
Development timeline for Pizensy
| Date | Article |
|---|---|
| Mar 2, 2020 | Approval FDA Approves Pizensy (lactitol) for the Treatment of Chronic Idiopathic Constipation in Adults |
| Feb 13, 2020 | Approval FDA Approves Pizensy (lactitol) for the Treatment of Chronic Idiopathic Constipation (CIC) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.